Veradermics schedules Phase 3 hair loss data
Veradermics, Incorporated will present top-line results from part B of its clinical Phase 3 study on Monday at 8:00 a.m. Eastern Time during an investor conference call.
The New Haven, Connecticut-based biopharmaceutical company announced the upcoming presentation through a press release covered by de.investing.com.
The randomized, double-blind, placebo-controlled trial, designated as “Study 302,” enrolled more than 500 men. The participants presented with mild to moderate androgenetic alopecia, commonly known as pattern hair loss. The investigation evaluates VDPHL01, an investigational oral formulation of minoxidil designed with a sustained-release profile.
VDPHL01 uses a non-hormonal gel matrix for sustained release
- Sustained-Release Delivery: The therapy utilizes a gel matrix designed to release the active pharmaceutical ingredient continuously over time rather than all at once.
- Non-Hormonal Compound: VDPHL01 operates as a systemic, non-hormonal treatment currently moving through late-stage clinical evaluation for both male and female pattern hair loss.
- Regulatory Milestones: The company designed Study 302 specifically to support future regulatory filings, marking a potential shift in a therapeutic category that has seen few new prescription approvals in decades.
Evaluating VDPHL01 in Study 302
Study 302 tests the efficacy and safety of the oral minoxidil candidate against a placebo control group. Veradermics designed the trial specifically to secure registration data for the compound. The investigation focuses exclusively on male participants presenting with early to moderate stages of the condition.
$MANE Veradermics: Phase 3 Hair Loss Trial Results to Be Discussed Monday at 8:00 AM ET ⠀ • Trial: Study 302 evaluated VDPHL01, an extended-release oral minoxidil formulation, in over 500 men with mild-to-moderate pattern hair loss. • Results: Company will review 12-month…
The company built the oral formulation around a specialized gel matrix. This technical approach aims to provide a continuous pharmacokinetic profile following ingestion. De.investing.com reported that the upcoming investor presentation will cover the primary endpoints and safety data gathered during this part of the trial.
| Trial Parameter | Study 302 Details |
|---|---|
| Phase and Design | Phase 3, randomized, double-blind, placebo-controlled |
| Participant Demographics | Over 500 men with mild to moderate androgenetic alopecia |
| Investigational Agent | VDPHL01 (oral sustained-release minoxidil) |
| Target Condition | Androgenetic alopecia (pattern hair loss) |
Androgenetic alopecia treatments
Androgenetic alopecia affects an estimated 80 million people in the United States alone. That total population includes 30 million women and 50 million men struggling with patterned hair thinning. Despite the high prevalence, therapeutic options remain limited across clinical practice.
De.investing.com noted that the biopharmaceutical sector has not introduced any new, FDA-approved prescription medications for this specific form of hair loss in nearly 30 years. Veradermics positions itself as a dermatologist-founded enterprise focusing entirely on addressing this clinical gap through late-stage drug development.
Side effects and medical precautions for oral minoxidil
Oral minoxidil formulations can cause systemic side effects, including changes in blood pressure and heart rate, and are strictly contraindicated in individuals with known hypersensitivity to the compound or severe cardiovascular disease. Pregnant individuals or those planning pregnancy must avoid certain hair loss medications due to teratogenic risks. Professional medical evaluation is essential to rule out underlying endocrinological or autoimmune causes of alopecia before initiating any therapeutic regimen.
Monday investor conference call
Management will host the webcast and accompanying presentation through the investor relations section of the corporate website. An archived recording of the event will remain accessible online following the conclusion of the live broadcast.
Financial analysts and market participants are monitoring the data release to gauge the commercial and regulatory viability of the drug candidate. Veradermics trades on the New York Stock Exchange under the ticker symbol MANE.
References
- Veradermics, Incorporated.
- de.investing.com.
